Hulskof schreef op 18 februari 2022 15:56:
Interessante hypothese op Discord:
I'm looking at the HIF2 transcription factor pathways. According to Merck/Peloton data, it seems like anemia is a hallmark of broad spectrum HIF2 antagonism?
Which means that if a drug just outright blocks HIF2, the patient is very likely going to end up with anemia. This is why this is the most common side effect of 2799.
In other words, HIF2 plays an important role in blood cell creation.
This is the part that we need to go into a little speculation: if blanket HIF2 antagonism means anemia, then what does HIF2 knockdown + no anemia mean?
That means our drugs are on target? And that we aren't ending up in non-cancer cells (much)?
If that's the case, then that means we have a high precision drug?
So no anemia is actually huge, especially so for HIF2
Kortom, als er amper anemia (bloedarmoede) optreedt én hif2 zou een belangrijke rol spelen in de aanmaak van bloedcellen, dan is het idd niet ondenkbeeldig dat ARO-HIF2 goed wordt afgeleverd, nl voor het overgrote deel in de kankercellen en niet elders. Anemia trad op in 12% vd gevallen. Dat is vooralsnog gunstig.